PL4065582T3 - Polimorficzne pochodne karbazolu i ich zastosowania - Google Patents

Polimorficzne pochodne karbazolu i ich zastosowania

Info

Publication number
PL4065582T3
PL4065582T3 PL20828454.7T PL20828454T PL4065582T3 PL 4065582 T3 PL4065582 T3 PL 4065582T3 PL 20828454 T PL20828454 T PL 20828454T PL 4065582 T3 PL4065582 T3 PL 4065582T3
Authority
PL
Poland
Prior art keywords
polymorphous
applications
carbazole derivatives
carbazole
derivatives
Prior art date
Application number
PL20828454.7T
Other languages
English (en)
Polish (pl)
Inventor
Alfredo C. Castro
Iii James Martin Nolan
Sarah Jean BETHUNE
Corinne Marie FOLBERTH
Original Assignee
Ikena Oncology, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ikena Oncology, Inc. filed Critical Ikena Oncology, Inc.
Publication of PL4065582T3 publication Critical patent/PL4065582T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL20828454.7T 2019-11-26 2020-11-25 Polimorficzne pochodne karbazolu i ich zastosowania PL4065582T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962940481P 2019-11-26 2019-11-26
PCT/US2020/062197 WO2021108528A1 (en) 2019-11-26 2020-11-25 Polymorphic carbazole derivatives and uses thereof

Publications (1)

Publication Number Publication Date
PL4065582T3 true PL4065582T3 (pl) 2025-08-18

Family

ID=73856339

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20828454.7T PL4065582T3 (pl) 2019-11-26 2020-11-25 Polimorficzne pochodne karbazolu i ich zastosowania

Country Status (14)

Country Link
US (3) US11591339B2 (https=)
EP (2) EP4065582B1 (https=)
JP (2) JP2023502531A (https=)
KR (1) KR20220125231A (https=)
CN (1) CN115279764B (https=)
AU (1) AU2020394424A1 (https=)
CA (1) CA3159317A1 (https=)
ES (1) ES3028099T3 (https=)
FI (1) FI4065582T3 (https=)
IL (1) IL293326A (https=)
MX (1) MX2022006308A (https=)
PL (1) PL4065582T3 (https=)
PT (1) PT4065582T (https=)
WO (1) WO2021108528A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
AU2020394424A1 (en) 2019-11-26 2022-06-16 Ikena Oncology, Inc. Polymorphic carbazole derivatives and uses thereof
US12570638B2 (en) 2020-05-20 2026-03-10 Sail Biomedicines, Inc. Fused imidazole derivatives as AHR antagonists

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274118A (en) 1962-01-22 1966-09-20 Lithium Corp Preparation of stable non-pyrophoric organometallic compositions
US5721356A (en) 1989-09-15 1998-02-24 Gensia, Inc. Orally active adenosine kinase inhibitors
US5962473A (en) 1996-08-16 1999-10-05 Eli Lilly And Company Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
EP1343506A1 (de) 2000-12-19 2003-09-17 MERCK PATENT GmbH Pharmazeutische formulierung enthaltend pyrazolo 4,3-d]pyrimidine und antithrombotica, calcium-antagonisten, prostaglandine oder prostaglandinderivate
EP2168576A3 (en) 2001-09-14 2010-05-26 Shionogi & Co., Ltd. Tricyclic compounds for treating dyslipidemia and arteriosclerotic diseases
ES2285164T3 (es) 2002-09-04 2007-11-16 Schering Corporation Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina.
MY133311A (en) 2002-09-19 2007-11-30 Schering Corp Novel imidazopyridines as cyclin dependent kinase inhibitors
JP4895806B2 (ja) 2003-04-09 2012-03-14 エクセリクシス, インク. Tie−2モジュレータと使用方法
AR047969A1 (es) 2004-02-25 2006-03-15 Schering Corp Pirazolotriazinas como inhibidores de quinasa
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ox40l抗體
JP2008520749A (ja) 2004-11-23 2008-06-19 レディ ユーエス セラピューティックス, インコーポレイテッド 新規二環式ヘテロ環化合物、その調製のためのプロセス、およびその新規二環式ヘテロ環化合物を含む組成物
PT2343320T (pt) 2005-03-25 2018-01-23 Gitr Inc Anticorpos anti-gitr e as suas utilizações
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
US8450351B2 (en) 2005-12-20 2013-05-28 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2008036642A2 (en) 2006-09-19 2008-03-27 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
WO2008058126A2 (en) 2006-11-06 2008-05-15 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
US10047066B2 (en) 2007-11-30 2018-08-14 Newlink Genetics Corporation IDO inhibitors
JP5643105B2 (ja) 2007-12-14 2014-12-17 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 新規イミダゾ[1,2−a]ピリジン及びイミダゾ[1,2−b]ピリダジン誘導体
WO2009156652A1 (fr) 2008-05-29 2009-12-30 Saint-Gobain Centre De Recherches Et D'etudes Europeen Structure en nid d'abeille a base de titanate d'aluminium
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
KR101790802B1 (ko) 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 항-gitr 항체
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
JP5802676B2 (ja) 2009-12-04 2015-10-28 センワ バイオサイエンシズ インコーポレイテッド Ck2阻害剤としてのピラゾロピリミジンおよび関連複素環化合物
ES2722300T3 (es) 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
EP2542256B1 (en) 2010-03-04 2019-05-22 MacroGenics, Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
JP5989547B2 (ja) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトcsf−1rに対する抗体及びその使用
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
HRP20190047T1 (hr) 2010-05-04 2019-02-22 Five Prime Therapeutics, Inc. Protutijela koja se vežu na csf1r
MX337040B (es) 2010-09-09 2016-02-09 Pfizer Moleculas de union a 4-1bb.
WO2012044562A2 (en) 2010-09-30 2012-04-05 Merck Sharp & Dohme Corp. Pyrazolopyrimidine pde10 inhibitors
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
GB201103837D0 (en) 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
NO2694640T3 (https=) 2011-04-15 2018-03-17
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン,エルエルシー B7−h1およびpd−1に結合する抗体およびその他の分子
AP2013007253A0 (en) 2011-04-21 2013-11-30 Origenis Gmbh Pyrazolo [4,3-D] pyrimidines useful as kinase inhibitors
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-pd-l1 항체 및 그의 용도
EP2788476B1 (en) 2011-12-08 2019-05-22 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
RU2658603C2 (ru) 2011-12-15 2018-06-21 Ф.Хоффманн-Ля Рош Аг Антитела против человеческого csf-1r и их применения
KR20140127855A (ko) 2012-02-06 2014-11-04 제넨테크, 인크. Csf1r 억제제를 사용하는 조성물 및 방법
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
AR090650A1 (es) 2012-04-12 2014-11-26 Alcon Res Ltd Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo
RU2670743C9 (ru) 2012-05-11 2018-12-19 Файв Прайм Терапьютикс, Инк. Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
WO2014060112A1 (en) 2012-10-19 2014-04-24 Origenis Gmbh Pyrazolo[4,3-d]pyrimidines as kinase inhibitors
WO2014138485A1 (en) 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof
MX388871B (es) * 2014-06-27 2025-03-20 Nogra Pharma Ltd Moduladores del receptor arilo y metodos para elaborar y usar los mismos.
CN108290855A (zh) 2015-07-01 2018-07-17 西北大学 被取代的喹唑啉化合物及其调节葡糖脑苷脂酶活性的用途
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
TW201841916A (zh) 2017-04-12 2018-12-01 美商麥珍塔治療學股份有限公司 芳香烴受體拮抗劑及其用途
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
EP3867253A4 (en) 2018-10-16 2022-05-18 Ikena Oncology, Inc. Indole ahr inhibitors and uses thereof
AU2020394424A1 (en) 2019-11-26 2022-06-16 Ikena Oncology, Inc. Polymorphic carbazole derivatives and uses thereof
EP4065090A1 (en) 2019-11-26 2022-10-05 Ikena Oncology, Inc. Ahr inhibitors and uses thereof
CA3167283A1 (en) 2020-01-10 2021-07-15 Ikena Oncology, Inc. Ahr inhibitors and uses thereof
MX2023004847A (es) 2020-10-28 2023-07-11 Ikena Oncology Inc Combinación de un inhibidor del receptor de hidrocarburos de arilo (ahr) con un inhibidor de pdx o doxorrubicina.

Also Published As

Publication number Publication date
WO2021108528A1 (en) 2021-06-03
JP2025113368A (ja) 2025-08-01
US20230286990A1 (en) 2023-09-14
US20250276975A1 (en) 2025-09-04
CN115279764B (zh) 2026-04-07
EP4529955A3 (en) 2025-07-16
US12162884B2 (en) 2024-12-10
EP4065582B1 (en) 2025-02-19
KR20220125231A (ko) 2022-09-14
EP4065582A1 (en) 2022-10-05
MX2022006308A (es) 2022-06-22
FI4065582T3 (fi) 2025-05-25
US11591339B2 (en) 2023-02-28
AU2020394424A1 (en) 2022-06-16
EP4529955A2 (en) 2025-04-02
CN115279764A (zh) 2022-11-01
PT4065582T (pt) 2025-05-22
JP2023502531A (ja) 2023-01-24
IL293326A (en) 2022-07-01
CA3159317A1 (en) 2021-06-03
ES3028099T3 (en) 2025-06-18
US20210253579A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
PL3917616T3 (pl) Związki heterocykliczne i ich zastosowanie
PL3946464T3 (pl) Związki i ich koniugaty
SI4067344T1 (sl) Cikloalkil-sečninski derivati
IL292161A (en) New methylquinazolinone derivatives
EP3845532A4 (en) QUINOLINO-PYRROLIDIN-2-ONE DERIVATIVE AND APPLICATION THEREOF
EP3594203A4 (en) SUBSTITUTED PYRROLIDINE COMPOUND AND ITS USE
EP3594202A4 (en) SUBSTITUTED PYRROLIDINE COMPOUND AND ITS USE
LT3830085T (lt) Deuterinti lanifibranoro dariniai
EP4013751C0 (en) 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES
DK3768669T3 (da) Piperazinazaspiroderivater
EP4077334C0 (en) FUROINDAZOLE DERIVATIVES
EP4021904C0 (en) ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES
HUE072194T2 (hu) Triazolil-metil-szubsztituált alfa-D-galaktopiranozid származékok
PL3710485T3 (pl) Koniugaty lek-przeciwciało anty-sez6 i sposoby ich stosowania
EP3681877C0 (en) PYRAZOLE DERIVED COMPOUND AND ITS USE
DK3898637T3 (da) Rapamycin-derivater
EP3884940A4 (en) Novel imidazole derivative
EP3533422C0 (en) Flat foot orthosis
EP3856755A4 (en) Terpinoid derivatives and uses thereof
DK4034535T3 (da) Aza-quinolinforbindelser og anvendelser deraf
EP4011898A4 (en) 3-hydroxy-5-pregnane-20-one derivative and use thereof
DK3823970T3 (da) Yderligere substituerede triazoloquinoxalinderivater
IL310931A (en) 6-aza-quinoline derivatives and related uses
DK3919498T6 (da) Pyrrolopyrimidinderivat og anvendelse deraf
PL4065582T3 (pl) Polimorficzne pochodne karbazolu i ich zastosowania